整合遗传和成像数据用于阿尔茨海默病的诊断和解释
Yanfei Wang1, Qing Wang1, Minghao Zhou1
1Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL, 32608, USA.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|August 11, 2025
概括
阿尔茨海默病的诊断得到了AlzCLIP的改进,这是一个新的AI模型,集成了遗传和脑成像数据. 这种方法提高了预测准确度,并揭示了神经退行性疾病的关键遗传和结构风险因素.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 人工智能的人工智能
背景情况:
- 阿尔茨海默病 (AD) 诊断依赖于有限的单模数据,影响准确性和可解释性.
- 遗传风险因素和大脑结构变化是AD病变的关键.
- 整合多模式数据为改善诊断和机械洞察提供了潜在的潜力.
研究的目的:
- 介绍AlzCLIP,这是一种针对阿尔茨海默病的新型对比学习框架.
- 将单核酸多态 (SNP) 概况和MRI成像特征统一到一个联合表示中.
- 提高阿尔茨海默病的诊断准确性和生物解释性.
主要方法:
- 开发了AlzCLIP,这是一个对比式学习框架,集成了SNP数据和MRI衍生成像功能.
- 在阿尔茨海默病神经成像计划 (ADNI) 和英国生物银行 (UKB) 队列中接受AlzCLIP的培训和评估.
- 利用特征重要性和相互作用分析来实现模型可解释性.
主要成果:
- 阿尔兹CLIP表现出强大的诊断性能,高达19%的表现超过了基线.
- 确定了关键的AD风险贡献者:SNP (rs1135173,rs7575209,rs66763080) 和结构标记 (海马体积,前皮质表面积).
- 发现了基因型特异性影响,例如rs11077054,与白质过强度和杏仁体缩有关.
结论:
- AlzCLIP有效地整合了多模式基因组和成像数据,以提高阿尔茨海默病风险预测.
- 该框架提供了对阿尔茨海默病变的生物学基础的见解.
- 阿尔茨克利普有可能改善临床诊断和对阿尔茨海默病机制的理解.
相关概念视频
Alzheimer's Disease: Overview
668
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
668
Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261


